SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma

[1]  Weijie Cao,et al.  GM-CSF impairs erythropoiesis by disrupting erythroblastic island formation via macrophages , 2021, Journal of translational medicine.

[2]  Huiyu Zhuang,et al.  FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma , 2021, Journal of Translational Medicine.

[3]  Chunhong Li,et al.  M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Jifeng Yu,et al.  Targeting CD47 for cancer immunotherapy , 2021, Journal of Hematology & Oncology.

[5]  Tao Huang,et al.  The Scavenger Receptor MARCO Expressed by Tumor-Associated Macrophages Are Highly Associated With Poor Pancreatic Cancer Prognosis , 2021, Frontiers in Oncology.

[6]  Seth D. Crockett,et al.  Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. , 2021, Gastroenterology.

[7]  C. Hillyer,et al.  Impairment of human terminal erythroid differentiation by histone deacetylase 5 deficiency. , 2021, Blood.

[8]  Zhengxue Quan,et al.  Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment , 2021, Experimental Hematology & Oncology.

[9]  I. Flinn,et al.  Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies , 2021, Clinical Cancer Research.

[10]  Caroline H. Johnson,et al.  Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients , 2021, Journal of Translational Medicine.

[11]  Kongming Wu,et al.  Regulation of PD-L1 expression in the tumor microenvironment , 2021, Journal of Hematology & Oncology.

[12]  Yongping Song,et al.  Erythroblastic Island Macrophages Shape Normal Erythropoiesis and Drive Associated Disorders in Erythroid Hematopoietic Diseases , 2021, Frontiers in Cell and Developmental Biology.

[13]  Jun Wu,et al.  Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment , 2020, Journal of Translational Medicine.

[14]  Li-Yu Daisy Liu,et al.  Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness , 2020, Cancer Cell International.

[15]  D. Lane,et al.  Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells , 2020, Proceedings of the National Academy of Sciences.

[16]  Junjian Liu,et al.  Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity , 2020, Cancer Immunology, Immunotherapy.

[17]  Hong Chang,et al.  Role of CD47 in Hematological Malignancies , 2020, Journal of Hematology & Oncology.

[18]  Wanzun Lin,et al.  Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups , 2020, Frontiers in Oncology.

[19]  Xi Chen,et al.  YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling , 2020, Journal of Translational Medicine.

[20]  Lu Xie,et al.  Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma , 2020, Cancer Cell International.

[21]  Jing Chen,et al.  CD86+/CD206+ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma , 2020, PeerJ.

[22]  Xiaoshun He,et al.  Macrophage Phenotype and Function in Liver Disorder , 2020, Frontiers in Immunology.

[23]  P. Vyas,et al.  The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results , 2019, Blood.

[24]  M. Tallman,et al.  A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results , 2019, Blood.

[25]  J. Pons,et al.  A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma , 2019, Blood.

[26]  Akintunde Akinleye,et al.  Immune checkpoint inhibitors of PD-L1 as cancer therapeutics , 2019, Journal of Hematology & Oncology.

[27]  Yaomei Wang,et al.  Identification and transcriptome analysis of erythroblastic island macrophages. , 2019, Blood.

[28]  Rachel E. Brewer,et al.  CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy , 2019, Nature.

[29]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[30]  Huiyin Lan,et al.  Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications , 2019, Journal of Hematology & Oncology.

[31]  Jia Fan,et al.  Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors , 2019, Theranostics.

[32]  Yun-Gui Yang,et al.  Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma , 2019, Cell Research.

[33]  L. Jia,et al.  Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release , 2019, EBioMedicine.

[34]  M. Konopleva,et al.  Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience , 2019, Journal of Hematology & Oncology.

[35]  R. Kariya,et al.  Attenuation of CD47-SIRPα Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic Metastasis , 2018, Translational oncology.

[36]  Marieke E. Ijsselsteijn,et al.  Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data , 2018, bioRxiv.

[37]  J. Brosseau,et al.  Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis , 2018, The Journal of clinical investigation.

[38]  M. Kudo,et al.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.

[39]  A. Veillette,et al.  SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy. , 2018, Trends in immunology.

[40]  Ya-jun Guo,et al.  Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses , 2018, mAbs.

[41]  T. Pawlik,et al.  Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection. , 2017, Journal of hepatology.

[42]  Publisher's Note , 2018, Anaesthesia.

[43]  I. Weissman,et al.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy , 2017, Nature Immunology.

[44]  G. Gores,et al.  Emerging molecular therapeutic targets for cholangiocarcinoma. , 2017, Journal of hepatology.

[45]  Linping Xu,et al.  Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma , 2017, Journal of immunology research.

[46]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[47]  Zihai Li,et al.  Is CD47 an innate immune checkpoint for tumor evasion? , 2017, Journal of Hematology & Oncology.

[48]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[49]  K. Garcia,et al.  Durable antitumor responses to CD47 blockade require adaptive immune stimulation , 2016, Proceedings of the National Academy of Sciences.

[50]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[51]  J. Berzofsky,et al.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. , 2014, Cancer research.

[52]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[53]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[54]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[55]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[56]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[57]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[58]  S. H. van der Burg,et al.  Identification and manipulation of tumor associated macrophages in human cancers , 2011, Journal of Translational Medicine.

[59]  I. Weissman,et al.  Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. , 2011, Blood.

[60]  H. Baba,et al.  Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma , 2010, Cancer science.

[61]  P. Allavena,et al.  Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.

[62]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[63]  H. Gresham,et al.  Cd47-Signal Regulatory Protein α (Sirpα) Regulates Fcγ and Complement Receptor–Mediated Phagocytosis , 2001, The Journal of experimental medicine.